Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald,...
STK11, KEAP1, and SMARCA4 confer resistance in metastatic NSCLC. But new data from ASCO 2026 add nuance to the story. Biagio Ricciuti, MD, PhD, walks through three studies asking whether dual immunotherapy, KRAS status, and mutation type change the calculus...
VS-7375, an investigational oral KRAS G12D (ON/OFF) inhibitor, demonstrated encouraging clinical activity and a favorable safety and tolerability profile across multiple dose levels and tumor types in the ongoing phase 1/2 TARGET-D 101 trial (NCT07020221), according to a news release...
Next-Generation KRAS Inhibitors Show Promising Activity in Advanced Non–Small Cell Lung Cancer Two investigational KRAS inhibitors showed activity in previously treated KRAS-mutant non–small cell lung cancer (NSCLC), according to findings presented during the Clinical Trials Plenary Session at the 2026...
A new two-step approach could make KRAS-targeted therapy more durable: start with KRAS inhibitors to shrink tumors, then add treatments that block DTPs’ glutamine metabolism and lysosome function to erase remaining cancer cells and curb relapse. Chiba University’s Shigeki Aoki...
